cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'sclc', 'nsclc', 'cabozantinib', 'cosmic-021']
#asco22 dr. presents nsclc data from cosmic-021 study (multi-cohort phase ib) including cohort 7 (atezolizumab + cabozantinib) and cohort 20 (cabozantinib alone). different cohorts - not a randomized study. heavily pretreated and largely io refractory. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him